Role of Ascorbic Acid Infusion in Critically Ill Patients With Transfusion Related Acute Lung Injury

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 21% of the time (143 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-07-16. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lunginjuryacutepatientstherapy
  Phrases that lowered it: to investigateinvestigate themalepressureblood
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 6.7% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Blinding: single (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Maximum age: 64 (lowers risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 63.3% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 10 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 244222 (lowers risk) · Drug's FDA history
• Responsible party: sponsor (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury NCT02106975 · started 2014 · scored riskier than 92% of active trials completed
• SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI) NCT04344184 · started 2020 · scored riskier than 88% of active trials completed
• Ascorbic Acid (Vitamin C) Infusion in Human Sepsis NCT01434121 · started 2010 · scored riskier than 88% of active trials completed
• High Dose Vitamin C in the Critically Ill Patient NCT01587963 · started 2013 · scored riskier than 72% of active trials terminated
• High Dose Intravenous Ascorbic Acid in Severe Sepsis NCT02734147 · started 2016 · scored riskier than 89% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.